Daily Archives: October 20, 2021
CDC Study: Pfizer vaccine showed 93% effectiveness against Covid-19 hospitalization among children aged 12-18 years.
20 Oct, 2021 | 10:31h | UTC
Commentary on Twitter (thread – click for more)
Vaccination reduced the risk of hospitalization among 12–18-year-olds by 93%, according to a new CDC study. No vaccinated adolescents died or were admitted to the ICU.
— Dr. Tom Frieden (@DrTomFrieden) October 19, 2021
Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.
20 Oct, 2021 | 10:27h | UTCCommentary: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University
Related:
A primer on what we know about mixing and matching Covid vaccines.
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
Study from Sweden assessing heterogenous vaccination in 3,445,061 individuals who received AZ as the first dose and either #pfizer, #moderna, or #AZ as second dose showed the following vaccine effectiveness:
AZ/Pfizer- 67%
AZ/Moderna- 79%
AZ/AZ- 50%https://t.co/UN0pey2kJ2— Yan Leyfman, MD (@YLeyfman) October 19, 2021
Should You Mix and Match Your Booster Shot?
20 Oct, 2021 | 10:25h | UTCShould You Mix and Match Your Booster Shot? – The Atlantic
Related:
A primer on what we know about mixing and matching Covid vaccines.
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19.
20 Oct, 2021 | 10:28h | UTCNews release: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases
[Preprint] Observational study in Brazil showed the J&J vaccine adjusted effectiveness was 50.9% against any symptomatic Covid-19, 72.9% for hospitalization, 92.5% for ICU admission, 88.7% for mechanical ventilation, and 90.5% for death.
20 Oct, 2021 | 10:24h | UTC
Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes.
20 Oct, 2021 | 10:20h | UTC
WHO Policy Brief: The urgent need to implement patient blood management.
20 Oct, 2021 | 10:15h | UTCThe urgent need to implement patient blood management: policy brief – World Health Organization
Covid-19: New mutation of Delta variant under close watch in UK.
20 Oct, 2021 | 10:21h | UTCCovid-19: New mutation of Delta variant under close watch in UK – BBC
WHO’s 7 policy recommendations on building resilient health systems.
20 Oct, 2021 | 10:18h | UTCNews release: WHO’s 7 policy recommendations on building resilient health systems – World Health Organization
WHO Position Paper: Building health systems resilience for universal health coverage and health security during the COVID-19 pandemic and beyond
Commentary on Twitter (thread – click for more)
#COVID19 has shown that there can be no lasting economic development without #HealthForAll & protection against health emergencies. Here are WHO’s 7⃣ recommendations on building resilient health systems based on #PrimaryHealthCare & #HealthSecurity.
? https://t.co/pp5Gh9BTnz pic.twitter.com/0d021b5ylf
— World Health Organization (WHO) (@WHO) October 19, 2021
Systematic Review: anti-interleukin-13 or anti-interleukin-4 agents may be appropriate for adults with moderate-to-severe uncontrolled asthma who have not responded to other treatments.
20 Oct, 2021 | 10:19h | UTC
Commentary on Twitter (thread – click for more)
Lead author David Evans said “Approximately five to ten percent of people with asthma experience symptoms that are severe or difficult-to-treat… [1/3] pic.twitter.com/Nw606oSrX0
— CochraneAirways (@CochraneAirways) October 19, 2021
Users’ guides to the medical literature: how to interpret and use a clinical practice guideline or recommendation.
20 Oct, 2021 | 10:09h | UTCHow to Interpret and Use a Clinical Practice Guideline or Recommendation: Users’ Guides to the Medical Literature – JAMA (free for a limited period)
Author Interview: How to Interpret and Use a Clinical Practice Guideline
RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.
20 Oct, 2021 | 10:13h | UTCTirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Related:
Review: Athletes and Hypertension.
20 Oct, 2021 | 09:52h | UTCAthletes and Hypertension – Current Cardiology Reports
Large observational study suggests Tramadol is associated with increased risk of adverse outcomes compared to Codeine.
20 Oct, 2021 | 10:11h | UTCAssociation of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes – JAMA (free for a limited period)
Editorial: Tramadol, Codeine, and Risk of Adverse Outcomes – JAMA (free for a limited period)
Choosing Wisely in Pediatric Hospital Medicine: 5 New Recommendations to Improve Value.
20 Oct, 2021 | 09:58h | UTCSee complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Cohort study: Acute urinary retention may be a clinical marker of occult prostate cancer and other urogenital, colorectal, and neurological cancers.
20 Oct, 2021 | 09:50h | UTCAcute urinary retention and risk of cancer: population based Danish cohort study – The BMJ
Commentary on Twitter
This study finds that a first diagnosis of acute urinary retention in patients aged 50 years or older was a clinical marker not only for prostate cancer but also for other urogenital cancers and colorectal and neurological cancershttps://t.co/0f1Z93cqR0 @dceaarhus
— The BMJ (@bmj_latest) October 19, 2021
Things We Do for No Reason: fluid restriction for the management of acute decompensated heart failure in patients with reduced ejection fraction.
20 Oct, 2021 | 10:00h | UTCThings We Do for No Reason™: Fluid Restriction for the Management of Acute Decompensated Heart Failure in Patients With Reduced Ejection Fraction – Journal of Hospital Medicine (free for a limited period)
Commentary on Twitter
? Today’s Things We Do for No Reason ™️ from @JHospMedicine: Why do we think fluid restriction is important in managing ADHF? What’s the alternative? ?
? Sound off in the replies why you do or don’t follow this practice. ?#HeartFailure #ADHFhttps://t.co/QayZdqqNSd
— Society of Hospital Medicine (@SocietyHospMed) October 19, 2021
Systematic Review: Restricting access to poisons is associated with decreases in suicide by poisoning without an equivalent shift toward other methods.
20 Oct, 2021 | 09:48h | UTC
Commentary on Twitter
Important new study on suicide in @JAMAHealthForum. Restricting access to poisons is associated with reductions in suicide without an equivalent shift toward other methods. https://t.co/dINq3oIxvd pic.twitter.com/vEn9wOlprN
— David Juurlink (@DavidJuurlink) October 18, 2021